Kinase-targeted libraries: The design and synthesis of novel, potent, and selective kinase inhibitors

被引:88
作者
Akritopoulou-Zanze, Irini [1 ]
Hajduk, Philip J. [1 ]
机构
[1] Abbott Labs, Global Pharmaceut Res & Dev, Abbott Pk, IL 60044 USA
关键词
SCAFFOLD ORIENTED SYNTHESIS; BIOLOGICAL EVALUATION; BINDING;
D O I
10.1016/j.drudis.2008.12.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Protein kinases continue to hold tremendous promise for therapeutic intervention, and the search for novel, safe and efficacious kinase inhibitors has intensified over the past decade. Given that most kinases are readily inhibited by organic small molecules and that a wealth of structural data exists on kinase-inhibitor complexes, there has been almost universal success in the design and identification of potent kinase inhibitors. The issues of non-selectivity and congested IP space, however, present formidable challenges for the successful clinical development of these compounds. We describe a systematic approach implemented at Abbott to enable the rapid discovery and design of novel and potent kinase inhibitors that provide additional opportunities for targeting new intellectual property space and achieving acceptable selectivity profiles.
引用
收藏
页码:291 / 297
页数:7
相关论文
共 20 条
[1]   Ligand efficiency indices as guideposts for drug discovery [J].
Abad-Zapatero, C ;
Metz, JT .
DRUG DISCOVERY TODAY, 2005, 10 (07) :464-469
[2]   Scaffold oriented synthesis. Part 1: Design, preparation, and biological evaluation of thienopyrazoles as kinase inhibitors [J].
Akritopoulou-Zanze, I ;
Darczak, D ;
Sarris, K ;
Phelan, KM ;
Huth, JR ;
Song, DY ;
Johnson, EF ;
Jia, Y ;
Djuric, SW .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (01) :96-99
[3]   Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor [J].
Albert, DH ;
Tapang, P ;
Magoc, TJ ;
Pease, LJ ;
Reuter, DR ;
Wei, RQ ;
Li, JL ;
Guo, J ;
Bousquet, PF ;
Ghoreishi-Haack, NS ;
Wang, B ;
Bukofzer, GT ;
Wang, YC ;
Stavropoulos, JA ;
Hartandi, K ;
Niquette, AL ;
Soni, N ;
Johnson, EF ;
McCall, JO ;
Bouska, JJ ;
Luo, Y ;
Donawho, CK ;
Dai, YJ ;
Marcotte, PA ;
Glaser, KB ;
Michaelides, MR ;
Davidsen, SK .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (04) :995-1006
[4]   A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding [J].
Bogoyevitch, Marie A. ;
Fairlie, David P. .
DRUG DISCOVERY TODAY, 2007, 12 (15-16) :622-633
[5]   Protein kinases - the major drug targets of the twenty-first century? [J].
Cohen, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315
[6]   Components of successful lead generation [J].
Davis, AM ;
Keeling, DJ ;
Steele, J ;
Tomkinson, NP ;
Tinker, AC .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (04) :421-439
[7]   Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors [J].
Gracias, Vijaya ;
Ji, Zhiqin ;
Akritopoulou-Zanze, Irini ;
Abad-Zapatero, Cele ;
Huth, Jeffrey R. ;
Song, Danying ;
Hajduk, Philip J. ;
Johnson, Eric F. ;
Glaser, Keith B. ;
Marcotte, Patrick A. ;
Pease, Lori ;
Soni, Nirupama B. ;
Stewart, Kent D. ;
Davidsen, Steven K. ;
Michaelides, Michael R. ;
Djuric, Stevan W. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (08) :2691-2695
[8]   Fragment-based drug design: How big is too big? [J].
Hajduk, Philip J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (24) :6972-6976
[9]   NMR-based screening in drug discovery [J].
Hajduk, PJ ;
Meadows, RP ;
Fesik, SW .
QUARTERLY REVIEWS OF BIOPHYSICS, 1999, 32 (03) :211-240
[10]   Pursuing the leadlikeness concept in pharmaceutical research [J].
Hann, MM ;
Oprea, TI .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2004, 8 (03) :255-263